Smoking status and treatment outcomes of vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration
| Autor: | Neil Murray, Mark C Gillies, Jennifer J. Arnold, Daniel Barthelmes, Vuong Nguyen, Chui M G Cheung, Alexander F Vittorio |
|---|---|
| Přispěvatelé: | University of Zurich |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A Visual acuity Databases Factual genetic structures Treatment outcome Visual Acuity Angiogenesis Inhibitors chemistry.chemical_compound 0302 clinical medicine Registries 030212 general & internal medicine Aged 80 and over Smoking General Medicine Bevacizumab Vascular endothelial growth factor Treatment Outcome Intravitreal Injections Female Smoking status medicine.symptom 10018 Ophthalmology Clinic medicine.medical_specialty Recombinant Fusion Proteins Vision Disorders 610 Medicine & health 03 medical and health sciences Ranibizumab Internal medicine Age related medicine Humans In patient Aged Retrospective Studies business.industry Significant difference Macular degeneration medicine.disease Choroidal Neovascularization eye diseases Ophthalmology Receptors Vascular Endothelial Growth Factor chemistry Wet Macular Degeneration 030221 ophthalmology & optometry sense organs business Follow-Up Studies |
| Popis: | PURPOSE To assess whether smoking status affects 1-year visual outcomes in eyes treated with vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration. METHODS Retrospective analysis of data from a prospectively designed, multicenter, observational database. Nine hundred and eighty seven treatment-naive eyes of patients with neovascular age-related macular degeneration were tracked by the Fight Retinal Blindness! outcome registry in Australia, New Zealand, Singapore, and Switzerland who had documented smoking status at baseline and commenced vascular endothelial growth factor inhibitor therapy from January 2006 to December 2016. Generalized additive models were used to display visual acuity results. RESULTS There was a significant difference in mean improvement in visual acuity at 12 months between nonsmokers, ex-smokers, and current smokers (7.7 vs. 6.1 vs. 3.5 letters of change; P = 0.046) among patients who completed 12 months of treatment when adjusted for age, baseline visual acuity, and choroidal neovascular membrane lesion type and nested for practice. There was no significant difference in the median number of injections over 12 months of treatment by smoking status. Current smokers were a mean of 6.2 years younger than nonsmokers when they started treatment (P < 0.001). CONCLUSION This study found inferior 12-month visual outcomes in patients who continued to smoke while receiving vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|